|
Hemato-oncology
Geriatric risk model for older patients with diffuse large B-cell lymphoma (GERIAD): a prospective multicenter cohort study
Ho-Young Yhim, Yong Park, Jeong-A Kim, Ho-Jin Shin, Young Rok Do, Joon Ho Moon, Min Kyoung Kim, Won Sik Lee, Dae Sik Kim, Myung-Won Lee, Yoon Seok Choi, Seong Hyun Jeong, Kyoung Ha Kim, Jinhang Kim, Chang-Hoon Lee, Ga-Young Song, Deok-Hwan Yang, Jae-Yong Kwak
Korean J Intern Med. 2024;39(3):501-512. Published online January 30, 2024
Background/Aims: Optimal risk stratification based on simplified geriatric assessment to predict treatment-related toxicity and survival needs to be clarified in older patients with diffuse large B-cell lymphoma (DLBCL).
Methods: This multicenter prospective cohort study enrolled newly diagnosed pat..
|
|
|
Prognostic Significance Of Sequential 18f-fdg Pet/Ct During Frontline Treatment Of Peripheral T Cell Lymphomas
Ga-Young Song, Sung-Hoon Jung, Seo-Yeon Ahn, Mihee Kim, Jae-Sook Ahn, Je-Jung Lee, Hyeoung-Joon Kim, Jang Bae Moon, Su Woong Yoo, Seong Young Kwon, Jung-Joon Min, Hee-Seung Bom, Sae-Ryung Kang, Deok-Hwan Yang
Korean J Intern Med. 2024;39(2):327-337. Published online January 25, 2024
Background/Aims: The prognostic significance of 18F-fluorodeoxyglucose (FDG)-positron emission tomography-computed tomography (PET/CT) in peripheral T-cell lymphomas (PTCLs) are controversial. We explored the prognostic impact of sequential 18F-FDG PET/CT during frontline chemo..
|
|
|
The prognostic impact of reduced variant burden in elderly patients with acute myeloid leukemia treated with decitabine
Mihee Kim, TaeHyung Kim, Seo-Yeon Ahn, Jun Hyung Lee, Ju Heon Park, Myung-Geun Shin, Sung-Hoon Jung, Ga-Young Song, Deok-Hwan Yang, Je-Jung Lee, Seung Hyun Choi, Mi Yeon Kim, Jae-Sook Ahn, Hyeoung-Joon Kim, Dennis Dong Hwan Kim
Korean J Intern Med. 2023;38(4):534-545. Published online June 9, 2023
Background/Aims: We evaluated the role of next-generation sequencing (NGS)-based disease monitoring for elderly patients diagnosed with acute myeloid leukemia (AML) who received decitabine therapy.
Methods: A total of 123 patients aged > 65 years with AML who received decitabine were eligible. We an..
|
|
|
